Triamterene Functions as an Effective Nonsense Suppression Agent for MPS I-H (Hurler Syndrome)
Authors:
- Amna SiddiquiASAmna Siddiqui
- Halil DundarHDHalil Dundar
- Jyoti SharmaJSJyoti Sharma
- Aneta KaczmarczykAKAneta Kaczmarczyk
- Josh EcholsJEJosh Echols
- Yanying DaiYDYanying Dai
- Chuanxi Richard SunCSChuanxi Richard Sun
- Ming DuMDMing Du
- Zhong LiuZLZhong Liu
- Rui ZhaoRZRui Zhao
- Tim WoodTWTim Wood
- Shalisa SandersSSShalisa Sanders
Open Access
- 24 February 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (5) , 4521
Abstract
Mucopolysaccharidosis I-Hurler (MPS I-H) is caused by the loss of α-L-iduronidase, a lysosomal enzyme that degrades glycosaminoglycans. Current therapies cannot treat many MPS I-H manifestations. In this study, triamterene, an FDA-approved, antihypertensive diuretic, was found to suppress translation termination at a nonsense mutation associated with MPS I-H. Triamterene rescued enough α-L-iduronidase function to normalize glycosaminoglycan storage in cell and animal models. This new function of triamterene operates through premature termination codon (PTC) dependent mechanisms that are unaffected by epithelial sodium channel activity, the target of triamterene’s diuretic function. Triamterene represents a potential non-invasive treatment for MPS I-H patients carrying a PTC.Keywords
Funding Information
- Scientific and Technological Research Council of Turkey (TUBITAK-2219, 1059B1916000563, P30DK072482, R21OD019922, ROWE19R0, BEDWEL19G0, KKEELIN15XX0)
- National Institutes of Health (TUBITAK-2219, 1059B1916000563, P30DK072482, R21OD019922, ROWE19R0, BEDWEL19G0, KKEELIN15XX0)
- Cystic Fibrosis Foundation (TUBITAK-2219, 1059B1916000563, P30DK072482, R21OD019922, ROWE19R0, BEDWEL19G0, KKEELIN15XX0)
- Alabama Drug Discovery Alliance (TUBITAK-2219, 1059B1916000563, P30DK072482, R21OD019922, ROWE19R0, BEDWEL19G0, KKEELIN15XX0)
- University of Pennsylvania Orphan Disease Center (TUBITAK-2219, 1059B1916000563, P30DK072482, R21OD019922, ROWE19R0, BEDWEL19G0, KKEELIN15XX0)
This publication has 44 references indexed in Scilit:
- Attenuation of Nonsense-Mediated mRNA Decay Enhances In Vivo Nonsense SuppressionPLOS ONE, 2013
- The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouseMolecular Genetics and Metabolism, 2012
- Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome)Blood, 2011
- Epithelial Na+ Channel (ENaC), Hormones, and HypertensionJournal of Biological Chemistry, 2010
- Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutationMolecular Genetics and Metabolism, 2010
- Generation of human-induced pluripotent stem cellsNature Protocols, 2008
- Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicinJournal of Clinical Investigation, 2007
- Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutationsBioorganic & Medicinal Chemistry Letters, 2006
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- REVERSAL OF CLINICAL FEATURES OF HURLER'S DISEASE AND BIOCHEMICAL IMPROVEMENT AFTER TREATMENT BY BONE-MARROW TRANSPLANTATIONThe Lancet, 1981